Rafael Holdings (RFL) EBT Margin (2017 - 2026)
Rafael Holdings' (RFL) quarterly EBT Margin came in at 1620.11% in Q2 2026, up 17547.0% year-over-year from N/an in Q2 2025, and up 45.74% quarter-over-quarter from 2985.78% in Q1 2026.
Powered by 
Analysis
Rafael Holdings (RFL) EBT Margin (2017 - 2026) Analysis & Trends
Rafael Holdings (RFL) has reported EBT Margin for 10 consecutive years, with 1620.11% the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBT Margin rose 17547.0% year-over-year to 1620.11% in Q2 2026; TTM through Apr 2026 was 3183.27%, a 36154.0% increase from a year earlier, with the FY2025 full-year figure at 3620.07%, up 693896.0% from the prior year.
- EBT Margin was 1620.11% for Q2 2026 at Rafael Holdings, up from 2985.78% in the prior quarter.
- Over five years, EBT Margin peaked at 8985.29% in Q1 2024 and troughed at 19315.48% in Q2 2024.
- A 5-year average of 4168.49% and a median of 3783.95% in 2025 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin surged 5973768 bps in 2022 and tumbled 1683801 bps in 2024, its largest moves.
- Over 5 years, EBT Margin stood at 7431.43% in 2022, then advanced by 30 bps to 5202.94% in 2023, then sank by 38 bps to 7187.5% in 2024, then surged by 43 bps to 4083.33% in 2025, then surged by 60 bps to 1620.11% in 2026.
- The last three EBT Margin figures came in at 1620.11% (Q2 2026), 2985.78% (Q1 2026), and 4083.33% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -20,427.46% |
| 10 | Rafael Holdings | 117.57 Mn | 117.57 Mn | 171,000.00 | -1,620.11% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | -1,620.11% |
| Jan 31, 2026 | -2,985.78% |
| Oct 31, 2025 | -4,083.33% |
| Jul 31, 2025 | -3,484.57% |
| Apr 30, 2025 | -1,795.58% |
| Jan 31, 2025 | -6,892.21% |
| Oct 31, 2024 | -7,187.50% |
| Jul 31, 2024 | -2,994.55% |
| Apr 30, 2024 | -19,315.48% |
| Jan 31, 2024 | 8,985.29% |
| Oct 31, 2023 | -5,202.94% |
| Jul 31, 2023 | 2,151.47% |
| Apr 30, 2023 | -2,477.46% |
| Jan 31, 2023 | -4,638.57% |
| Oct 31, 2022 | -7,431.43% |
| Jul 31, 2022 | -6,731.88% |
| Apr 30, 2022 | -6,553.95% |
| Jan 31, 2022 | -2,774.32% |
| Oct 31, 2021 | -67,169.11% |
| Jul 31, 2021 | 492.41% |